Summary
The ligand–receptor interaction between some peptidomimetic inhibitors and a class II major histocompatibility complex (MHC)–peptide presenting molecule, the HLA-DR4 receptor, can be modeled using some 3D quantitative structure-activity relationship (QSAR) methods such as the comparative molecular field analysis (CoMFA) and some molecular descriptors using the Cerius2 program. The structures of these peptidomimetic inhibitors can be generated theoretically, and the conformations used in the 3D QSAR studies can be defined by aligning them against the known structure of HLA-DR4 receptor through a least-square fitting procedure. The best CoMFA models can be constructed using the aligned structures of the best fitting result. The principal components analysis (PCA) module of the Cerius2 program can be used to trim outliers of the CoMFA columns generated. Procedures for a direct QSAR analysis using the Cerius2 descriptors and regression analysis by the genetic function module are also presented
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Watts, C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 1997, 15, 821–850.
Rudensky, A.; Prestoa-Hurlburt, P.; Hong, S. C.; Barlow, A.; Janeway, C. A. Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991, 353, 622–627.
Chicz, R. M.; Urban, R. G.; Lone, W. S.; Gorga, J. C.; Stern, L. J.; Vignali, D. A.; Strominger, J. L. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992, 358, 764–768.
Tiwari, J.; Terasaki, P. HLA and disease association. Springer-Verlag, New York, 1985.
Rowley, M. J.; Stockman, A.; Bond, C. A.; Tait, B. D.; Rowley, G. L.; Sherritt, M. A.; Mackay, I. R.; Muirden, K. D.; Bernard, C. C. The effect of HLA-DRB1 disease susceptibility markers on the expression of RA. Scand. J. Rheumatol. 1997, 26, 448–455.
Weyand, C. M.; Goronzy, J. J. Inherited and noninherited risk factors in rheumatoid arthritis. Curr. Opin. Rheumatol. 1995, 7, 206–213.
Nepom, G. T.; Gersuk, V.; Nepom, B. S. Prognostic implications of HLA genotyping in the early assessment of patients with rheumatoid arthritis. J. Rheumatol. Suppl. 1996, 44, 5–9.
Wagner, U.; Kaltenhauser, S.; Sauer, H.; Arnold, S.; Seidel, W.; Hantzschel, H.; Kalden, J. R.; Wassmuth, R. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum. 1997, 40, 341-351.
Perdriger, A.; Chales, G.; Semana, G.; Guggenbuhl, P.; Meyer, O.; Quillivic, F.; Pawlotsky, Y. Role of HLA-DR-DR and DR-DQ association in the expression of extraarticular manifestations and rheumatoid factor in rheumatoid arthritis. J. Rheumatol. 1997, 24, 1272–1276.
Stern, L. J.; Brown, J. H.; Jardetzky, T. S.; Gorga, J. C.; Urban, R. G.; Strominger, J. L.; Wiley, D. C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994, 368, 215–221.
Jardetzky, T. S.; Brown, J. H.; Stern, L. J.; Urban, R. G.; Chi, Y. I.; Stauffacher C.; Strominger, J. L.; Wiley, D. C. Three dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994, 368, 711–718.
Ghosh, P.; Amaya, M.; Mellins, E.; Wiley, D. C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995, 378, 457–462.
Brown, J. H.; Jardetzky, T. S.; Gorga, J. C.; Stern, L. J.; Urban, R. G.; Strominger, J. L.; Wiley, D. C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993, 364, 33–39.
Dessen, A.; Lawrence, C. M.; Cupo, S.; Zaller, D. M.; Wiley, D. C. X-ray crystal structure of HLA-DR4 (DRA0101, DRB10401) complexed with a peptide from human collagen II. Immunity 1997, 7, 473–481.
Garboczi, D. N.; Ghosh, P.; Utz, F.; Oing, R.; Biddison, W. E.; Wiley, D. C. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996, 384, 134–141.
Garcia, K. C.; Degano, M.; Stanfield, R. L.; Brunmark, A.; Jackson, M. R.; Peterson, P. A.; Teyton, L.; Wilson, I. A. An α ß T cell receptor structure at 2.5Å and its orientation in the TCR-MHC complex. Science 1996, 274, 209–219.
Reinherz, E. L.; Tan, K.; Tang, L.; Kern, P.; Liu, J.; Xiong, Y.; Hussey, E.; Smolyar, A.; Hare, B.; Zhong, R.; Joachimiak, A.; Chang, H.; Wagner, G.; Wang, J. The crystal structure of a T-cell receptor in complex with peptide and MHC class II. Science 1999, 286, 1913–1921.
Hammer, J.; Takacs, B.; Sinigaglia, F.; Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J. Exp. Med. 1993, 176, 1007–1013.
Hammer, J.; Valsasnini, P.; Tolba, K.; Bolin, D.; Higelin, J.; Takacs, B.; Sinigaglia, F. Promiscuous and allele-specific anchors in HLA-DR binding peptides. Cell 1994, 74, 197–203.
Hammer, J.; Bono, E.; Gallazzi, F.; Belunis, C.; Nagy, Z. A.; Sinigaglia, F. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J. Exp. Med. 1995, 180, 2353–2358.
Hammer, J.; Callazzi, F.; Bono, E.; Karr, R. W.; Guenot, J.; Valsasin, P.; Nagy, Z. A.; Sinigaglia, F. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J. Exp. Med. 1995, 181, 1847–1855.
Bolin, D. R.; Swain, A. L.; Ramakanth, S.; Berthel, S. J.; Gillespie, P.; Huby, N. J. S.; Makofske, R.; Orzechowski, L.; Perrotta, A.; Toth, K.; Cooper, J. P.; Jiang, N.; Falcion, F.; Campbell, R.; Cox, D.; Gaizband, D.; Belunis, C. J.; Vidovic, D.; Ito, K.; Crowther, R.; Kammlott, U.; Zhang, X.; Palermo, R.; Weber, D.; Guenot, J.; Nagy, Z.; Olson, G. L. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationship, and X-ray crystal structure. J. Med. Chem. 2000, 43, 2135–2148.
Hennecke, J.; Wiley, D. C. Structure of a complex of the human α / ß T cell receptor (TCR) HA 1.7, influenza hemagglutinin peptide and major histocompatibility complex class II molecule, HLA-DR4 (DRA * 0101 and DRB1 * 0401): insight into TCR cross-restriction and alloreactivity. J. Exp. Med. 2002, 195, 571–581.
Zavala-Ruize, Z.; Sundberg, E. J.; Stone, J. D.; DeOliveira, D. B.; Chan, I. C.; Svendsent, J.; Mariuzza, R. A.; Stern, L. J. Exploration of the p6/p7 region of the peptide-binding site of the human class II major histocompatibility complex protein HLA-DR1. J. Biol. Chem. 2003, 278, 44904–44912.
SYBYL 7.1; The Tripos Associates; 1699. Hanley Road, St. Louis, MO, USA.
Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges, Tetrahedron 1980, 36, 3219–3228.
Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.; Alagona, G.; Profeta, S. Jr.; Weiner, P. A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc. 1984, 106, 765–784.
Golbraikh, A.; Tropsha, A. Beware of q2! J. Mol. Graph. Model. 2002, 20, 269–276.
Accelrys Inc.; Cerius2 Modeling Environment, Release 4.0, San Diego, Accelrys Inc., 2002.
Marshall, G. R.; Barry, C. D.; Bosshard, H. E.; Dammkoehler, R. A.; Dunn, D. A. The conformational parameter in drug design: the active analog approach. In Olson, E.C. and Christoffersen, R.E. (Eds.) Computer-Assisted Drug Design, ACS Symp. Series, Vol 112. American Chemical Society, Washington, DC. 1979, pp. 206–226.
Acknowledgment
This work is supported in part from a grant (NSC94-2313-B007-001) of National Science Council, Taiwan.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc.
About this protocol
Cite this protocol
Lin, TH. (2007). Predicting the MHC-Peptide Affinity Using Some Interactive-Type Molecular Descriptors and QSAR Models. In: Flower, D.R. (eds) Immunoinformatics. Methods in Molecular Biology™, vol 409. Humana Press. https://doi.org/10.1007/978-1-60327-118-9_17
Download citation
DOI: https://doi.org/10.1007/978-1-60327-118-9_17
Publisher Name: Humana Press
Print ISBN: 978-1-58829-699-3
Online ISBN: 978-1-60327-118-9
eBook Packages: Springer Protocols